PE20191815A1 - Formulaciones acuosas estables de adalimumab - Google Patents

Formulaciones acuosas estables de adalimumab

Info

Publication number
PE20191815A1
PE20191815A1 PE2019002434A PE2019002434A PE20191815A1 PE 20191815 A1 PE20191815 A1 PE 20191815A1 PE 2019002434 A PE2019002434 A PE 2019002434A PE 2019002434 A PE2019002434 A PE 2019002434A PE 20191815 A1 PE20191815 A1 PE 20191815A1
Authority
PE
Peru
Prior art keywords
adalimumab
stable aqueous
aqueous formulations
composition
histidine
Prior art date
Application number
PE2019002434A
Other languages
English (en)
Inventor
Mark Manning
Robert W Payne
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of PE20191815A1 publication Critical patent/PE20191815A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Referido a composicion farmaceutica acuosa de pH amortiguado que comprende adalimumab; solucion amortiguadora que consiste unicamente en histidina; y un estabilizante, tal como glicina, arginina, entre otros; en donde dicha composicion no contiene poliol.
PE2019002434A 2012-09-07 2013-09-06 Formulaciones acuosas estables de adalimumab PE20191815A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261698138P 2012-09-07 2012-09-07
US201361769581P 2013-02-26 2013-02-26
US201361770421P 2013-02-28 2013-02-28
PCT/US2013/058618 WO2014039903A2 (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab

Publications (1)

Publication Number Publication Date
PE20191815A1 true PE20191815A1 (es) 2019-12-27

Family

ID=50237778

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002434A PE20191815A1 (es) 2012-09-07 2013-09-06 Formulaciones acuosas estables de adalimumab
PE2015000306A PE20150964A1 (es) 2012-09-07 2013-09-06 Formulaciones acuosas estables de adalimumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015000306A PE20150964A1 (es) 2012-09-07 2013-09-06 Formulaciones acuosas estables de adalimumab

Country Status (31)

Country Link
US (39) US20140186361A1 (es)
EP (2) EP2892550B1 (es)
JP (3) JP6463268B2 (es)
KR (3) KR20220025196A (es)
CN (1) CN104768576A (es)
AR (1) AR092470A1 (es)
AU (3) AU2013312300A1 (es)
BR (1) BR112015004984A2 (es)
CA (2) CA2884182C (es)
CL (1) CL2015000574A1 (es)
CY (1) CY1123407T1 (es)
DK (1) DK2892550T3 (es)
DO (1) DOP2015000051A (es)
EA (2) EA029215B1 (es)
EC (1) ECSP15013227A (es)
ES (1) ES2784861T3 (es)
HK (1) HK1210601A1 (es)
HR (1) HRP20200434T1 (es)
HU (1) HUE049282T2 (es)
IL (2) IL237583B (es)
LT (1) LT2892550T (es)
MX (1) MX2015003007A (es)
PE (2) PE20191815A1 (es)
PL (1) PL2892550T3 (es)
PT (1) PT2892550T (es)
RS (1) RS60226B1 (es)
SG (2) SG10201705668XA (es)
SI (1) SI2892550T1 (es)
TW (2) TW202042841A (es)
UY (1) UY35351A (es)
WO (1) WO2014039903A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG11201405475UA (en) 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150110659A (ko) * 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CN106170298B (zh) 2013-10-16 2024-01-09 前瞻疗法公司 用于提高抗体稳定性的缓冲液制剂
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10688187B2 (en) * 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
PL2946765T3 (pl) * 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP3156071A4 (en) * 2014-06-10 2018-01-10 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab preparation
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
AU2016217806A1 (en) * 2015-02-13 2017-10-05 Sanofi Stable liquid formulation for monoclonal antibodies
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3402470A4 (en) * 2016-01-12 2019-11-13 Dr. Reddy's Laboratories Limited STABLE PHARMACEUTICAL COMPOSITION
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
JP2019511531A (ja) * 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
WO2017184880A1 (en) * 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
GEP20217249B (en) 2016-06-30 2021-04-26 Inc Celltrion Stable liquid pharmaceutical preparation
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
MA47106A (fr) * 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
AU2018236651B2 (en) * 2017-03-16 2020-12-10 Lg Chem, Ltd. Liquid formulation of anti-TNF alpha antibody
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CN111491664A (zh) * 2017-09-20 2020-08-04 阿尔沃科技Hf公司 阿达木单抗的药物制剂
US20220081478A1 (en) * 2019-01-11 2022-03-17 Samsung Bioepis Co., Ltd. Pharmaceutical composition comprising antibody, device comprising same, and use thereof
BR112021015034A2 (pt) * 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
AU2020337093A1 (en) * 2019-08-30 2022-04-21 Kashiv Biosciences, Llc Novel formulation of highly concentrated pharmacologically active antibody
EP4119161A1 (en) * 2020-03-13 2023-01-18 Samsung Bioepis Co., Ltd. Liquid pharmaceutical composition having improved stability
US20230158143A1 (en) * 2020-05-21 2023-05-25 Shilpa Medicare Ltd Pharmaceutical compositions comprising adalimumab
WO2022187834A1 (en) * 2021-03-03 2022-09-09 Allakos Inc. Anti-siglec-8 antibody formulations
WO2023037384A1 (en) * 2021-09-07 2023-03-16 Dr. Reddy's Laboratories Limited Formulations of immune check point inhibitors or like
WO2023043232A1 (ko) * 2021-09-16 2023-03-23 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
WO2023183898A1 (en) * 2022-03-24 2023-09-28 Arch Oncology, Inc. Formulations for anti-cd47 antibodies

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CZ286714B6 (en) 1994-08-08 2000-06-14 Debiopharm Sa Pharmaceutically stable preparation based on oxaliplatinum
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0938334A4 (en) 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6171686B1 (en) 1997-10-03 2001-01-09 Marine Environmental Solutions, L.L.C. Synthetic aquatic structure
PT917879E (pt) 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DK2272870T3 (da) 1998-06-09 2013-08-05 Csl Behring Ag Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
TR200503572T2 (tr) 1999-03-25 2006-04-21 Knoll Gmbh & Co. Kg. Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
WO2000061169A1 (en) 1999-04-09 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
WO2002011753A1 (fr) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ES2674888T3 (es) 2001-06-26 2018-07-04 Amgen Inc. Anticuerpos para OPGL
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
MXPA04008215A (es) 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004004780A1 (en) 2002-07-09 2004-01-15 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4500683B2 (ja) 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
ES2553987T3 (es) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
WO2006022599A1 (en) 2004-08-27 2006-03-02 Marian Metke Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CN101822820A (zh) 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
CA2685372A1 (en) 2007-05-02 2008-11-13 F. Hoffmann-La Roche Ag Method for stabilizing a protein
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US20090151807A1 (en) 2007-08-07 2009-06-18 Davis Chanda Janese Container Insert for Zero Headspace
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20190045414A (ko) * 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN104188911A (zh) * 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
CN102301235B (zh) 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
CN102245206A (zh) 2008-12-09 2011-11-16 弗·哈夫曼-拉罗切有限公司 获得无赋形剂抗体溶液的方法
JP2012526121A (ja) 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
DK3721904T3 (da) 2009-11-20 2021-11-15 Biocon Ltd Formuleringer af t1h-antistof
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
EP2542221A4 (en) * 2010-03-01 2013-10-23 Cytodyn Inc CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
WO2011141926A2 (en) 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
CH703405B1 (de) 2010-07-05 2014-05-15 Melexis Tessenderlo Nv Magnetischer Winkelsensor.
PL3333188T3 (pl) * 2010-08-19 2022-05-09 Zoetis Belgium S.A. Przeciwciała anty-ngf i ich zastosowanie
TW201213342A (en) * 2010-09-17 2012-04-01 Baxter Int Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral pH
RU2015154965A (ru) * 2010-11-11 2019-01-16 Эббви Байотекнолоджи Лтд. Улучшенные высококонцентрированные жидкие препараты антител против tnf альфа
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
RU2614257C2 (ru) 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc
US20150182525A1 (en) 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
DK2726090T3 (da) 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
BR112014010186A2 (pt) 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
SG11201405475UA (en) 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150102042A1 (en) 2012-07-10 2015-04-16 Gary Matsch Air Purging Lid
WO2014099636A1 (en) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
CN102988984B (zh) 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
EP2996621B1 (en) 2013-05-13 2018-06-20 EndoChoice, Inc. An endoscope tip position visual indicator and heat management system
US9681695B2 (en) 2013-07-31 2017-06-20 Sport Maska Inc. Helmet with chin cup

Also Published As

Publication number Publication date
JP2021020930A (ja) 2021-02-18
US20180028656A1 (en) 2018-02-01
RS60226B1 (sr) 2020-06-30
WO2014039903A2 (en) 2014-03-13
US10780163B2 (en) 2020-09-22
UY35351A (es) 2014-08-29
US20180311352A1 (en) 2018-11-01
US20160304600A1 (en) 2016-10-20
US9737600B2 (en) 2017-08-22
US9724414B2 (en) 2017-08-08
US10799585B2 (en) 2020-10-13
US20180028653A1 (en) 2018-02-01
US9731008B2 (en) 2017-08-15
JP6783845B2 (ja) 2020-11-11
US20150190513A1 (en) 2015-07-09
US20160039926A1 (en) 2016-02-11
EA029215B1 (ru) 2018-02-28
KR20210040470A (ko) 2021-04-13
JP2015527402A (ja) 2015-09-17
US20180311349A1 (en) 2018-11-01
US10716854B2 (en) 2020-07-21
US9382317B2 (en) 2016-07-05
US10722579B2 (en) 2020-07-28
IL277652B2 (en) 2023-04-01
US10716853B2 (en) 2020-07-21
US20160303233A1 (en) 2016-10-20
US10155039B2 (en) 2018-12-18
US20170072054A1 (en) 2017-03-16
SI2892550T1 (sl) 2020-11-30
US9682145B2 (en) 2017-06-20
JP2019069993A (ja) 2019-05-09
US9782480B2 (en) 2017-10-10
DOP2015000051A (es) 2015-05-31
US20180311351A1 (en) 2018-11-01
MX2015003007A (es) 2015-06-05
US10207000B2 (en) 2019-02-19
PT2892550T (pt) 2020-03-27
US20160256546A1 (en) 2016-09-08
SG11201501715QA (en) 2015-05-28
US20180028654A1 (en) 2018-02-01
US20180043019A1 (en) 2018-02-15
US9724415B2 (en) 2017-08-08
PL2892550T3 (pl) 2020-07-27
KR102238677B1 (ko) 2021-04-12
US10159733B2 (en) 2018-12-25
US20150191538A1 (en) 2015-07-09
CA2884182A1 (en) 2014-03-13
US9757454B2 (en) 2017-09-12
US10195275B2 (en) 2019-02-05
KR20150047140A (ko) 2015-05-04
EP2892550A2 (en) 2015-07-15
PE20150964A1 (es) 2015-07-25
EP3701968A1 (en) 2020-09-02
BR112015004984A2 (pt) 2017-07-04
AU2013312300A1 (en) 2015-04-16
US10159732B2 (en) 2018-12-25
US10286072B2 (en) 2019-05-14
US9861695B2 (en) 2018-01-09
US9782479B2 (en) 2017-10-10
US20160303235A1 (en) 2016-10-20
AU2020202912A1 (en) 2020-05-21
US9346880B2 (en) 2016-05-24
US9340612B2 (en) 2016-05-17
US20180311350A1 (en) 2018-11-01
US20150190512A1 (en) 2015-07-09
US20180140701A1 (en) 2018-05-24
EA201590518A1 (ru) 2016-05-31
SG10201705668XA (en) 2017-08-30
IL237583B (en) 2020-10-29
US20160304599A1 (en) 2016-10-20
TW202042841A (zh) 2020-12-01
US20180043018A1 (en) 2018-02-15
EP2892550A4 (en) 2016-04-13
US20180028655A1 (en) 2018-02-01
US20180021433A1 (en) 2018-01-25
US20180028657A1 (en) 2018-02-01
US20190070294A1 (en) 2019-03-07
US20190070293A1 (en) 2019-03-07
US20160256545A1 (en) 2016-09-08
US9808525B2 (en) 2017-11-07
US9770507B2 (en) 2017-09-26
US20150191539A1 (en) 2015-07-09
EA201791717A1 (ru) 2018-03-30
US20160304601A1 (en) 2016-10-20
US20190070292A1 (en) 2019-03-07
CN104768576A (zh) 2015-07-08
AR092470A1 (es) 2015-04-22
CA3153799A1 (en) 2014-03-13
ES2784861T3 (es) 2020-10-01
US20170312361A1 (en) 2017-11-02
US20160031982A1 (en) 2016-02-04
US9789185B2 (en) 2017-10-17
US10772960B2 (en) 2020-09-15
LT2892550T (lt) 2020-04-10
US20190060455A1 (en) 2019-02-28
US20160256547A1 (en) 2016-09-08
JP6463268B2 (ja) 2019-01-30
HRP20200434T1 (hr) 2020-07-24
HUE049282T2 (hu) 2020-09-28
US10688183B2 (en) 2020-06-23
WO2014039903A3 (en) 2014-06-26
TWI698253B (zh) 2020-07-11
US20150182626A1 (en) 2015-07-02
AU2018208699A1 (en) 2018-08-16
US9707293B2 (en) 2017-07-18
TW201424749A (zh) 2014-07-01
US20140186361A1 (en) 2014-07-03
KR20220025196A (ko) 2022-03-03
US9340611B2 (en) 2016-05-17
US20160303234A1 (en) 2016-10-20
IL277652B (en) 2022-09-01
US10772959B2 (en) 2020-09-15
EP2892550B1 (en) 2019-12-18
US10286071B2 (en) 2019-05-14
KR102362829B1 (ko) 2022-02-15
US20160263226A1 (en) 2016-09-15
CL2015000574A1 (es) 2015-10-23
US20180055929A1 (en) 2018-03-01
DK2892550T3 (da) 2020-03-30
US10716852B2 (en) 2020-07-21
ECSP15013227A (es) 2016-01-29
CA2884182C (en) 2022-06-14
US10786566B2 (en) 2020-09-29
IL237583A0 (en) 2015-04-30
US20180055930A1 (en) 2018-03-01
US9731009B2 (en) 2017-08-15
HK1210601A1 (en) 2016-04-29
IL277652A (en) 2020-11-30
CY1123407T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
PE20191815A1 (es) Formulaciones acuosas estables de adalimumab
CL2017001139A1 (es) Composiciones de antibiótico
GT201400164A (es) Compuestos de imidazopirrolidinona
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112013004818A2 (pt) "agente de controle de peste"
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CU20140090A7 (es) COMPUESTOS ß- LACTÁMICOS SUSTITUIDOS CON AMINA, SU PREPARACIÓN Y USO COMO AGENTES BACTERIANOS
MA33976B1 (fr) Spiroindolinone pyrrolidines
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
BR112015003591A8 (pt) Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
ECSP18010481A (es) Composiciones de plinabulina
BR112015000520A2 (pt) agente de espessamento estável com lipase
IN2015DN03029A (es)
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
TR201902602T4 (tr) Yağ bazlı haşere öldürücü süspansiyon.
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
CR20120521A (es) Combinaciones de principios activos
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso